Download PDF
Horm Metab Res 2023; 55(09): 610-616
DOI: 10.1055/a-2051-6776
Original Article: Endocrine Care

The Value of Visfatin in the Prediction of Metabolic Syndrome: A Systematic Review and Meta-Analysis

Yingling Jiang
1   Zhuzhou Hospital Affiliated to Central South University, Zhuzhou, China
,
Lihua Zhou
1   Zhuzhou Hospital Affiliated to Central South University, Zhuzhou, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Various studies have shown that visfatin may be connected to metabolic syndrome (MS). However, epidemiological studies yielded conflicting outcomes. The purpose of this article was to highlight the relationship between the plasma visfatin level and MS risk by conducting a meta-analysis of available literature. A comprehensive literature search of eligible studies was done up to January 2023. Data were presented as standard mean difference (SMD). Observational methodological meta-analysis was conducted to assess the relationships between visfatin levels and MS. The visfatin levels between patients with MS or not were calculated by SMD and 95% confidence interval (CI) using the random-effects model. Funnel plot (visually inspect publication bias), Egger’s linear regression test and Begger’s linear regression test were applied to describe the risk of publication bias. A sensitivity analysis was performed via sequentially omitting each of the study one by one. In total, 16 eligible studies comprising 1016 cases and 1414 healthy controls finally enrolled in the current meta-analysis for pooling meta-analysis. Overall, the meta-analysis results revealed that visfatin levels in MS patients were significantly greater than that of controls group (SMD: 0.60, 95% CI=0.18–1.03, I2=95%, p<0.001). The results of the subgroup analysis showed that gender did not affect the results of meta-analysis. This meta-analysis shed light on the fact that circulating visfatin levels were significantly higher in patients with MS than in the controls group. Visfatin may a chance to predict the occurrence of MS.

Key words

visfatin - metabolic syndrome - meta-analysis


Publication History

Received: 14 February 2023

Accepted after revision: 09 March 2023

Accepted Manuscript online:
09 March 2023

Article published online:
25 May 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kumari R, Kumar S, Kant R. An update on metabolic syndrome: metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab Syndr 2019; 13: 2409-2417
    CrossrefPubMedGoogle Scholar
  • 2 Fumeron F, Lamri A, Khalil CA. et al. Dairy consumption and the incidence of hyperglycemia and the metabolic syndrome: results from a french prospective study, data from the epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care 2011; 34: 813-817
    CrossrefPubMedGoogle Scholar
  • 3 Wassink AM, Graaf YVD, Soedamah-Muthu SS. et al. Metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease. Diab Vasc Dis Res 2008; 5: 114-122
    CrossrefPubMedGoogle Scholar
  • 4 Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812-819
    CrossrefPubMedGoogle Scholar
  • 5 Esposito K, Capuano A, Giugliano D. Metabolic syndrome and cancer: holistic or reductionist?. Endocrine 2014; 45: 362-364
    CrossrefPubMedGoogle Scholar
  • 6 Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol 2010; 25: 375-384
    CrossrefPubMedGoogle Scholar
  • 7 Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752
    CrossrefPubMedGoogle Scholar
  • 8 Al-Dokhi LM. Adipokines and etiopathology of metabolic disorders. Saudi Med J 2009; 30: 1123-1132
    PubMedGoogle Scholar
  • 9 Fukuhara A, Matsuda M, Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430
    CrossrefPubMedGoogle Scholar
  • 10 Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008; 15: 1851-1862
    CrossrefPubMedGoogle Scholar
  • 11 Yang CC, Deng SJ, Hsu CC. et al. Visfatin regulates genes related to lipid metabolism in porcine adipocytes. J Anim Sci 2010; 88: 3233-3241
    CrossrefPubMedGoogle Scholar
  • 12 Wang P, Xu TY, Guan YF. et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 2009; 81: 370-380
    CrossrefPubMedGoogle Scholar
  • 13 Swartz MK. The PRISMA statement: a guideline for systematic reviews and meta-analyses. J Pediatr Health Care 2011; 25: 1-2
    CrossrefPubMedGoogle Scholar
  • 14 Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13
    CrossrefPubMedGoogle Scholar
  • 15 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605
    CrossrefPubMedGoogle Scholar
  • 16 Lin CC, Lai MM, Li TC. et al. Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res Clin Pract 2009; 85: 24-29
    CrossrefPubMedGoogle Scholar
  • 17 Huang JF, Huang CF, Yu ML. et al. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection. J Gastroenterol Hepatol 2011; 26: 530-535
    CrossrefPubMedGoogle Scholar
  • 18 Chang X, Jiao Y, Lu J. et al. Adiponectin and visfatin may serve as diagnosis markers for metabolic syndrome in Uygur population. Int J Clin Exp Med 2014; 7: 4322-4326
    PubMedGoogle Scholar
  • 19 Shu KH, Wu MJ, Chen CH. et al. Serum adipokine levels in renal transplant recipients. Transplant Proc 2014; 46: 381-384
    CrossrefPubMedGoogle Scholar
  • 20 Olszanecka-Glinianowicz M, Kocełak P, Nylec M. et al. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci 2012; 8: 214-218
    CrossrefPubMedGoogle Scholar
  • 21 Baranowska-Bik A, Uchman D, Litwiniuk A. et al. Peripheral levels of selected adipokines in patients with newly diagnosed multiple sclerosis. Endokrynol Pol 2020; 71: 109-115
    CrossrefPubMedGoogle Scholar
  • 22 Güdücü N, İsçi H, Görmüş U. et al. Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome. J Endocrinol Invest 2013; 36: 157-161
    CrossrefPubMedGoogle Scholar
  • 23 Kural B, Değer O, Erem C. et al. Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. Turk J Med Sci 2014; 44: 1021-1028
    CrossrefPubMedGoogle Scholar
  • 24 Esteghamati A, Morteza A, Zandieh A. et al. The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis. J Cardiovasc Transl Res 2012; 5: 541-546
    CrossrefPubMedGoogle Scholar
  • 25 Samsam-Shariat SZ, Bolhasani M, Sarrafzadegan N. et al. Relationship between blood peroxidases activity and visfatin levels in metabolic syndrome patients. ARYA Atheroscler 2014; 10: 218-226
    PubMedGoogle Scholar
  • 26 Elfassy Y, Bongrani A, Levy P. et al. Relationships between metabolic status, seminal adipokines, and reproductive functions in men from infertile couples. Eur J Endocrinol 2020; 182: 67-77
    CrossrefPubMedGoogle Scholar
  • 27 Filippatos TD, Derdemezis CS, Kiortsis DN. et al. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007; 30: 323-326
    CrossrefPubMedGoogle Scholar
  • 28 Iacobellis G, Iorio M, Napoli N. et al. Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest 2011; 34: e12-e15
    CrossrefPubMedGoogle Scholar
  • 29 Kolsgaard ML, Wangensteen T, Brunborg C. et al. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest 2009; 69: 858-864
    CrossrefPubMedGoogle Scholar
  • 30 de Luis DA, Aller R, Gonzalez Sagrado M. et al. Serum visfatin levels and metabolic syndrome criteria in obese female subjects. Diabetes Metab Res Rev 2013; 29: 576-581
    CrossrefPubMedGoogle Scholar
  • 31 Jialal I, Devaraj S, Kaur H. et al. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab 2013; 98: E514-E517
    CrossrefPubMedGoogle Scholar
  • 32 Cekmez F, Cekmez Y, Pirgon O. et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. Eur Cytokine Netw 2011; 22: 32-37
    CrossrefPubMedGoogle Scholar
  • 33 Romacho T, Azcutia V, Vázquez-Bella M. et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009; 52: 2455-2463
    CrossrefPubMedGoogle Scholar
  • 34 Ognjanovic S, Bao S, Yamamoto SY. et al. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001; 26: 107-117
    CrossrefPubMedGoogle Scholar
  • 35 Li RZ, Ma XN, Hu XF. et al. Elevated visfatin levels in obese children are related to proinflammatory factors. J Pediatr Endocrinol Metab 2013; 26: 111-118
    PubMedGoogle Scholar
  • 36 Zhong M, Tan HW, Gong HP. et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008; 69: 878-884
    CrossrefPubMedGoogle Scholar